ScinoPharm Taiwan Ltd (TWSE:1789), a process R&D and API manufacturing service provider to the global pharmaceutical industry, announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS).
According to ScinoPharm Taiwan, it is the only pharmaceutical company in Taiwan to achieve this milestone.
The company says that it is actively progressing regulatory submissions and forging collaborations across Europe, Asia, and emerging markets to expand its international presence in the generic drug product market and build on its already strong position on the generic API front.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval